Company intelligence / Profile preview
Yingkai Saiwei
Beijing, Beijing, Chinainnovotherapeutics.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Innovo Therapeutics is a clinical-stage biopharmaceutical company based in Beijing, China, specializing in the development of innovative small molecule drugs and targeted protein degradation (PROTAC) therapies. The company focuses on addressing unmet medical needs in oncology and autoimmune diseases through its proprietary drug discovery platforms. Its pipeline includes several candidates targeting key disease drivers, with lead programs currently in early-stage clinical trials. Innovo aims to leverage its expertise in medicinal chemistry and biology to deliver next-generation precision medicines.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Small moleculeProteolysis-targeting chimera therapy
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Yingkai Saiwei.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Yingkai Saiwei.